Roche (OTCQX: RHHBY) launched a large-scale hybrid-cloud NVIDIA AI factory on 16 March 2026, adding 2,176 Blackwell GPUs to reach a total exceeding 3,500 GPUs across on-premise and cloud infrastructure.

The platform embeds AI across R&D, manufacturing, diagnostics and digital health, supporting Lab-in-the-Loop, digital twins, accelerated genomic and pathology analysis, and conversational healthcare AI to speed drug and diagnostic development.


Loading…

Loading translation…

Positive


2,176 Blackwell GPUs added on premises across US and Europe

Combined GPU footprint now exceeds 3,500 Blackwell GPUs

AI factory embedded across R&D, manufacturing, diagnostics workflows

Lab-in-the-Loop scale-up enabling larger hypothesis testing and model building

Ongoing strategic collaboration with NVIDIA since 2023




On the day this news was published, RHHBY declined 1.07%, reflecting a mild negative market reaction.







Data tracked by StockTitan Argus on the day of publication.














03/16/2026 – 04:30 PM


With the addition of 2,176 NVIDIA Blackwell GPUs, Roche now operates the pharmaceutical industry’s largest announced hybrid-cloud AI factory, totaling more than 3,500 GPUs. The new computational infrastructure supports Roche’s vision of building an AI-accelerated healthcare organisation.NVIDIA AI factories help accelerate discoveries, enable more efficient clinical trials, and unlock data insights at scale, ultimately advancing innovation and improved healthcare outcomes.

Basel, 16 March 2026 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that an expansion of its global AI infrastructure, deploying a large-scale AI factory powered by a full stack of the latest-generation NVIDIA accelerated computing and AI. Featuring 2,176 high-performance GPUs on premises across the United States and Europe and embedded across the entire value chain, this infrastructure is designed to accelerate the development of diagnostics solutions and therapeutics. With this most recent investment, Roche’s combined on-premise and cloud GPU infrastructure now exceeds 3,500 Blackwell GPUs, which is the greatest announced GPU footprint available to a pharmaceutical company.

This computational expansion marks the next phase of a strategic NVIDIA collaboration that started in 2023. By leveraging NVIDIA AI infrastructure, Roche accelerates drug development through high-quality data and groundbreaking AI.

“In healthcare, time is the most critical variable; every day saved means a life-changing medicine or diagnostic reaches a patient sooner,” said Wafaa Mamilli, Roche’s Chief Digital and Technology Officer. “Our AI factory combines world-class computing power with Roche’s scientific expertise to embed AI across the entire value chain — from discovery to development, manufacturing and commercialisation — transforming how we deliver the next generation of medicines and diagnostics solutions.”

Roche’s AI factory is a high-performance supercomputing platform that powers digital transformation across the organisation. In R&D, the NVIDIA BioNeMo platform enhances Roche’s Lab-in-the-Loop, where biological and chemistry experiments are connected with Roche’s AI models. This helps scientists test hypotheses at scale, accelerate progress, and make discoveries that were not possible otherwise. In manufacturing, digital twins — virtual replicas of production lines — powered by NVIDIA Omniverse libraries, allow engineers to optimize processes and factory designs. In diagnostics, accelerated computing and NVIDIA Parabricks software enable insights across vast datasets. In digital pathology, the technologies scan a large number of images to detect subtle disease patterns. In digital health, Roche uses NVIDIA NeMo Guardrails to ensure safe and reliable healthcare-grade conversational AI.

“Our expanded collaboration with NVIDIA and the launch of this AI factory further strengthens our leadership in AI-driven drug discovery and development,” said Aviv Regev, Executive Vice President and Head of Genentech Research and Early Development (gRED). “By providing the massive computational power needed to continue to scale our Lab-in-the-Loop strategy — a space we have pioneered for over five years — our scientists can build more sophisticated predictive frontier models and further shorten the path from biological insight to life-saving medicine.”

Artificial Intelligence at Roche
The implementation of the AI factory is a cornerstone of Roche’s broader digital transformation. For Roche, AI is a key capability designed to augment or complement human expertise. By expanding access to supercomputing capabilities across the organisation, the company empowers its global workforce to tackle the most complex challenges in human disease. Roche’s vision for AI is fundamentally about accelerating the journey toward preventing, stopping, and curing diseases.

About Roche
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.

For over 125 years, sustainability has been an integral part of Roche’s business. As a science-driven company, our greatest contribution to society is developing innovative medicines and diagnostics that help people live healthier lives. Roche is committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045.

Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

Roche Global Media Relations
Phone: +41 61 688 8888 / e-mail: media.relations@roche.com

Hans Trees, PhD
Phone: +41 79 407 72 58Nathalie Altermatt
Phone: +41 79 771 05 25

 

Lorena Corfas
Phone: +41 79 568 24 95Simon Goldsborough
Phone: +44 797 32 72 915

 

Karsten Kleine
Phone: +41 79 461 86 83Kirti Pandey
Phone: +41 79 398 38 53

 

Yvette Petillon
Phone: +41 79 961 92 50Dr Rebekka Schnell
Phone: +41 79 205 27 03

Roche Media Release NVIDIA AI factory English





FAQ

How many GPUs did Roche add to its AI factory on March 16, 2026 (RHHBY)?

Roche added 2,176 NVIDIA Blackwell GPUs on March 16, 2026. According to the company, this expansion increases Roche’s combined on-premise and cloud GPU infrastructure to more than 3,500 GPUs, the largest announced pharmaceutical footprint.

What does Roche’s AI factory mean for drug discovery and clinical development (RHHBY)?

The AI factory accelerates hypothesis testing and model development for drug discovery and trials. According to the company, it scales Lab-in-the-Loop, supports predictive models, and aims to shorten the path from biological insight to medicine.

Where will Roche’s new NVIDIA GPUs be deployed and what functions will they support (RHHBY)?

The GPUs are deployed on premises across the United States and Europe to support R&D, manufacturing, diagnostics and digital health. According to the company, they power Lab-in-the-Loop, digital twins, Parabricks genomics, and pathology analytics.

How does Roche use NVIDIA software and platforms within the AI factory (RHHBY)?

Roche uses NVIDIA BioNeMo, Omniverse, Parabricks and NeMo Guardrails across functions. According to the company, these tools enable biological modeling, digital twins, accelerated genomics, and safer conversational healthcare AI.

Does the March 16, 2026 expansion change Roche’s partnership with NVIDIA (RHHBY)?

The expansion extends a strategic collaboration that began in 2023 and deepens technical integration. According to the company, the larger AI factory further strengthens joint capabilities for AI-driven discovery and development.